Vertex Pharmaceuticals price target raised to $296 from $293 at Piper Sandler

Piper Sandler analyst Do Kim raised the firm’s price target on Vertex Pharmaceuticals to $296 from $293 and keeps a Neutral rating on the shares. Focus should continue to increase on late-stage pipelines as cystic fibrosis growth slows, the analyst tells investors. While Kim expects exa-cel to be approved, the timing of this may be a risk due to it being the first gene-editing based therapy to be approved.